In his work as a scientist, he focused on the mechanism and three-dimensional molecular structures of proteins using x-ray crystallography. This scientific background has allowed Matthew to successfully litigate major patent disputes involving biologics, an extremely competitive and technically complex field.

Representative Work

Represented Bristol-Myers Squibb, Ono Pharmaceutical Co. and Nobel laureate Dr. Tasuku Honjo in multiple patent infringement litigations against AstraZeneca related to anti-PD-L1 and anti-CTLA-4 antibodies. Succeeded in obtaining favorable settlement for all cases.
Counsel for innovator pharmaceutical company and two research institutions in ongoing ANDA actions involving challenges by multiple generic manufacturers to compound, polymorph, and method of treatment patents protecting multi-billion dollar cancer therapy.
Represented Bristol-Myers Squibb, Ono Pharmaceutical Co. and Japanese immunologist Dr. Tasuko Honjo in patent litigation involving revolutionary immuno-oncology treatment methods. The team’s work contributed to a worldwide settlement that included an initial payment by defendant Merck & Co., Inc. of $625 million and payment of ongoing royalties through 2026.
Represented plaintiff 3M Company in a patent infringement dispute against competitor Kerr Corporation involving 3M’s innovative dental composite materials. After successive victories for 3M in connection with Markman proceedings and Daubert motions, the case settled in December 2019.
Represented pharmaceutical companies in the correction of inventorship action related to patents involving methods of treatment for cancer with biologics.

Served as part of the trial team that won a jury verdict for client Janssen Biotech Inc. in a patent infringement case brought by Abbott GmbH & Co. The jury returned a verdict that claims in two patents asserted against Janssen’s antibody drug product Stelara® were invalid. Responsible for direct and cross-examination of technical experts.
Represented pharmaceutical companies in patent litigation involving immuno-oncology treatment methods.
Represented a pharmaceutical company in Abbreviated New Drug Application litigation related to chemical synthesis of pharmaceutical ingredients.
Served as part of a trial team that, in 2009, won a $1.67 billion patent jury verdict—reported at the time by Bloomberg to be the largest in U.S. history—for clients Centocor Ortho Biotech and New York University against Abbott Laboratories for its flagship product, Humira®.

“Matthew is technically gifted and balances confidence with humility like few others I have met.”

“He is thorough and smart, looks around corners, and he puts together bulletproof reports.”

Chambers USA, 2024

Education
J.D., University of Pennsylvania Law School, summa cum laude, 2005
Ph.D., Cornell University, 1999
B.S., Michigan State University, with high honors, 1993

Clerkships
U.S.D.C., District of Delaware
U.S.C.A., 3rd Circuit

Bar Admissions
Delaware
Pennsylvania
U.S. Patent and Trademark Office

Recognitions

Chambers USA, Intellectual Property, 2024.
The Legal 500 US, Patents: Litigation (Full Coverage), 2021-2024.
Philadelphia Business Journal, Best of the Bar: Philadelphias Top Lawyers, 2020.
IAM Patent 1000—The World’s Leading Patent Professionals, Leading Private Patent Litigator in Philadelphia, 2019-2021, 2024.
Super Lawyers, Pennsylvania, Intellectual Property Litigation, 2013-2018.

Speeches and Publications